Description:

This lecture will outline and describe the current understanding of thyroid eye disease (TED) and its interrelation with Graves' Disease.  It will describe incidence, risk factors, and associated systemic signs, symptoms, and pathophysiology including Rundle's curve.  We will discuss treatment options for TED including the recent FDA approval of Teprotumumab, its clinical trials, study endpoints, and adverse reactions.  Masquerading ocular findings that may be early signs of TED will be described as well as lab testing that can help with the early detection of TED will be discussed.  Doctors have a knowledge need for this practice gap which means having the knowledge of how to detect, diagnose, and treat TED in an integrated, multidisciplinary method.

Course Code:

AOA363-SD

Speaker(s):

Jacob Lang, O.D.

drjakelang@gmail.com

Selina McGee, O.D.

drmcgee@bespokevision.org

Credits:

1

AOA Expiration Date:

12/7/2025

Related News

Taking eye care advocacy to a global scale

Roger Jordan, O.D., one of optometry’s most effective and honored advocates in the U.S., was recently named to lead a key World Council of Optometry committee. On the committee, he will help shape optometry around the globe.

Level up your optometric surgical team: AOA launches surgical assistant coursework

The AOA’s new micro-credential program for optometric surgical assisting delivers big with a thoughtfully designed course that equips your clinic staff with specialized knowledge and skills.

4 essential personal financial tools for optometrists

Learn how AOAExcel® endorsed business partner Laurel Road can help maximize your finances.